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Group schema-focused therapy enriched
with psychomotor therapy versus
treatment as usual for older adults with
cluster B and/or C personality disorders: a
randomized trial
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Abstract
Background: Several types of psychotherapy have been proven successful in the treatment of personality disorders
in younger age groups, however studies among older patients are lacking. We developed a group schema-focused
therapy (SFT) enriched with psychomotor therapy (PMT) for older adults with cluster B and/or C personality
disorders. This paper describes the design of a randomized controlled trial (RCT). We will evaluate the (cost-)
effectiveness of this therapy protocol in specialized mental health care. We hypothesize that our treatment program
is cost-effective and superior to treatment as usual (TAU) in reducing psychological distress and improving quality
of life in older adults treated to specialized mental healthcare.
Methods: A multicenter RCT with a one-year follow-up comparing group schema-focused therapy enriched with
psychomotor therapy (group SFT + PMT) and TAU for adults aged 60 years and older who suffer from either a
cluster B and/or C personality disorder. The primary outcome is general psychological distress measured with the
53-item Brief Symptom Inventory. Secondary outcomes are the Schema Mode Inventory (118-item version) and the
Young Schema Questionnaire. Cost-effectiveness analysis will be performed from a societal perspective with the
EuroQol five dimensions questionnaire and structured cost-interviews.
Discussion: This study will add to the knowledge of psychotherapy in later life. The study specifically contributes to
the evidence on (cost-) effectiveness of group SFT enriched with PMT adapted to the needs of for older adults with
cluster b and/or c personality.
Trial registration: Netherlands Trial Register NTR 6621. Registered on 20 August 2017.
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Background
The prevalence rate of personality disorders among
community-dwelling older people is estimated at 8% [1]
and varies between 33 and 58% among older people re-
ferred to specialized mental health care [2–4]. The dis-
ease burden due to personality disorders is high for
patients (lowered quality of life, high levels of psycho-
logical distress and a high suicide risk) as well as for so-
ciety (increased medical consumption and informal care)
[5, 6]. For example, maladaptive personality traits are as-
sociated with a 16–30% increase in somatic healthcare
consumption among older adults [7, 8]. Adequate detec-
tion and treatment is therefore warranted from both a
patient and societal perspective. Even in specialized
mental health care for older adults, personality disorders
often remain undiagnosed and undertreated [9, 10].
Among younger patients several psychological therapies,
among which schema focused therapy (SFT) have been
developed that effectively reduce the burden of personal-
ity disorders [11, 12]. SFT addresses how early maladap-
tive schemas influence daily life and interpersonal
relationships. Schemas pertain to one’s core conceptions
of self, others and the world. They are formed in child-
hood and adolescence. In case of adverse circumstances,
maladaptive schemas and associated coping styles will de-
velop to survive (emotionally) which later on, in a health-
ier environment will lead to interpersonal dysfunctional
coping and emotional instability. SFT helps patients to
identify their most important maladaptive schemas and to
respond in a more adaptive manner when these maladap-
tive schemas are triggered in daily life.
Review studies in adults (< 60 years) on the treatment
for personality disorders concluded that SFT improves
quality of life for the borderline personality disorder.
They found a recovery from psychological symptoms
and that it was less expensive compared to usual care
[12]. The aforementioned studies focused on the border-
line personality disorder [11] for which SFT was origin-
ally developed [13]. However, effectiveness of SFT has
also been proven for the avoidant personality disorder
[14], mixed group personality disorders [15], and more
recently for the chronic mood- and anxiety disorders
[16, 17]. Although SFT is generally delivered in an indi-
vidual format, group SFT is considered to speed up and
amplify the effects of individual SFT [18]. Even so-called
short-term group SFT [19] is associated with improve-
ments in affective symptoms as well as personality path-
ology. Studies in younger and middle aged patients
which tested the association between the effect of SFT
and age did not find a significant impact of age [18, 20].
Extrapolation of these findings to older samples may
suggest that SFT also remains effective in later life. Of all
psychotherapies focused on personality disorders, SFT is
considered most relevant for geriatric practice due to its
favorable effects on comorbid, often longstanding affective
disorders [21–23]. To date, only three uncontrolled stud-
ies of SFT among older adults have been published [9].
These studies point to favorable effects of SFT in later life.
First, among 51 depressed inpatients, SFT led to improve-
ment of depressive symptoms, anxiety and five out of the
seven maladaptive schemas [24]. Second, among 31 Dutch
older outpatients, group SFT improved psychological
distress with effect-sizes similar to those reported for
younger patients. Moreover, changes in early maladaptive
schemas mediated change in psychological distress in this
latter study [21]. Third, in a multiple-baseline case series
study among 8 older persons suffering from a cluster C
personality disorder, psychopathology remained stable
during an extended baseline period, while psychopath-
ology significantly diminished during treatment and
follow-up [25].
Although these studies among older patients are
promising, some caution is needed since no randomized
controlled studies evaluating SFT in later life have been
conducted yet [9]. Therefore, we decided to perform
such a randomized controlled trial and to present its
study design here. SFT protocols examined among older
patients up to now highly relied on cognitive techniques.
Since cognitive techniques may become less effective
with increasing age [26], we added several experiential
techniques. These techniques are considered powerful
methods to change early maladaptive schemas in older
adults [21]. Not only did we add experiential techniques
to the traditional, verbal SFT approach, we also enriched
our treatment protocol with PMT. By offering PMT, pa-
tients will experience how their schemas influence their
behavior and feelings. The ‘learning by doing’ approach
offers opportunities to try out new behaviors [27]. More-
over, discovering the origin of feelings and physical sen-
sations is an important therapeutic mechanism of SFT.
PMT contributes to this important ingredient of SFT, by
using bodily awareness and physical activities to let
patients experience the way they tend to behave [28].
During the preparation phase of this trial, we ran five
treatment groups to refine our protocol and test its
feasibility. Participants of these pilot groups highly ap-
preciated the psychomotor therapy, the experiential
techniques and the adaptation of SFT to a geriatric
population, in general.
Study objectives
The aim of this article is to describe the design of a RCT
examining the (cost-)effectiveness of group SFT enriched
with PMT compared to treatment as usual for older pa-
tients suffering from a cluster B and/or C personality dis-
order. We hypothesize that our treatment program is
cost-effective and superior to treatment as usual (TAU) in
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reducing psychological distress and improving quality of life
in older adults treated to specialized mental healthcare.
Methods
Design
We designed a multi-center randomized controlled trial
with two parallel treatment groups: 20 sessions of group
SFT enriched with PMT delivered over a 6-months
period, versus treatment as usual (TAU) for older adults
with cluster B and/or C personality disorders in special-
ized mental health care. Primary outcome is general
psychological distress. In addition, cost-effectiveness of the
intervention from a societal perspective is evaluated.
Outcome measurements will be administered pre- and
post-treatment as well as at 6 and 12months post-
treatment. Six mental health care organizations in the
Northern Netherlands agreed to participate, one university
department of geriatric psychiatry (University Medical
Center Groningen) and five affiliated mental health organi-
zations (GGZ Friesland van Andel department, GGZ
Drenthe, Lentis, Dimence and Mediant). The study has
been approved by the Medical Ethics Committee of the
University Medical Center Groningen on May 12th, 2017
(M17.212189) and was registered in the Dutch Trial Register
on August 20th, 2017 (NTR 6621).
Study population
Eligible are patients, 60 years or older with a cluster B
and/or C personality disorder according to the DSM-5
who are referred to or are currently treated at an out-
patient clinic for geriatric psychiatry of the participating
centres in the Netherlands. According to DSM-criteria,
the criterion threshold for diagnosing a personality
disorder in older patients is too strict [29, 30]. For that
reason we will also include older patients falling short
one content criterion for a specific cluster B and/or C
personality disorder, provided that they meet the general
diagnostic criteria for a personality disorder (hereafter
‘subthreshold cluster B/C personality disorder’). Older
patients generally endorse fewer specific personality
disorder criteria than younger age groups (29% of the
criteria contain measurement bias in older age groups),
while the latent variable structure for each personality
disorder suggests a similar severity level of personality
pathology [30]. Specific inclusion criteria are: 1) age of
60 years or above; 2) cluster B or C personality disorder
(or falling one content criterion short) as confirmed by
the Structured Clinical Interview for DSM-5 for person-
ality disorders (SCID-5-PD) [31] 3) mentally able to
adhere to the group SFT treatment schedule and to fill
out the schema (mode) questionnaires and 4) giving
informed consent after having received oral and written
information. Exclusion criteria are: 1) severe current
mental illness, including bipolar I disorder, psychosis, or
substance abuse disorders needing clinical detoxification; 2)
an established neurodegenerative disorder; 3) cognitive im-
pairment defined as a sum score below 23 points on the
Montreal Cognitive Assessment (MoCA) battery [32]; 4)
having received schema-focused therapy in the previous
year or during the current illness episode; and 5) suicide
risk interfering with adequate treatment delivery. Physical
restraints or physical frailty are no exclusion criterion.
Despite the group format, the PMT will be individually
adapted so that even the frailest patients can participate.
Recruitment
Mental health professionals working at the different sites
can inform patients about the study when a cluster B or C
personality disorder is suspected. After having received
oral and written study information from their mental
health professional interested potential eligible patients
will get an appointment with the clinical psychologist at
their clinic. During this screening session, the in- and ex-
clusion criteria for the study are formally checked by ad-
ministering amongst others the SCID-5-PD and MoCA
and any remaining questions the patient has about the
study are answered. For patients not meeting the in- and
exclusion criteria the study ends after this screening ses-
sion. Patients eligible for the study, will be given another 2
weeks to consider participation. Patients willing to partici-
pate in the study, will be asked to sign informed consent
and are put on a waiting-list. Only the patients who gave
written informed consent are included in the study. The
data from the screening appointment, will be passed on –
anonymously – for inclusion in the study database. When
a minimum of 8 and maximum of 16 patients have given
informed consent at a specific site, baseline measurements
will be conducted, after which participants will be ran-
domized (see flowchart) Fig. 1.
Sample size calculation
The only RCT comparing group SFT with TAU was con-
ducted among younger adults with borderline personal-
ity disorder and found a between group Cohen’s d effect
size (ES) of 2.0 on the Brief Symptom Inventory (BSI-53)
[33]. For our power analysis, we tuned down the ex-
pected ES to 0.5 (medium effect) for two reasons. First,
the ES of 2.0 was partly due to absence of an effect of
TAU [34] while meta-analysis of psychotherapy in geriat-
ric psychiatry shows an average pre-post ES of 0.4 for
TAU [17]. Second, an open study on group SFT reported
a pre-post Cohen’s d ES of 0.8 among older adults with
mixed cluster B and C personality disorders [21]. Apply-
ing a 2-sided alpha of 0.05 and a power of 80% to detect
an ES of 0.5, requires 63 patients per arm. Although
compensation for dropout is not necessary according to
the CONSORT criteria when performing intention to
treat analyses (http://www.consort-statement.org/), we
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aim to include 140 patients in order to compensate for
10% early dropouts during the waiting-list period. Differ-
ences in the scores between the intervention and control
group on the various outcome measures (BSI-53,
EQ-5D-5 L, YSQ and SMI) will be analyzed using linear
mixed-models accounting for missing data and relevant
confounders.
Randomisation, blinding and treatment allocation
A stratified block randomisation will be performed
aimed to assign participants evenly (1,1) over the two
conditions [35]. Randomisation will be performed per
study site and stratified by the presence of a full versus
subthreshold cluster B/C personality disorder (PD – 1
criterion). Participants will be randomized in blocks
when 8 to 16 consecutive patients have consented to
participate at a specific study site. Randomisation will be
performed centrally using online randomisation software
QuickCalcs of GraphPad (http://www.graphapd.com/
quickcalcs/randMenu).) by an independent investigator
who will be blind to patient characteristics. Patients will
be randomized in even patient numbers per stratum. In
case of an uneven number of participants per stratum,
the next even number of patients will be randomised
and the last allocation will be forwarded to the next
block randomisation with an uneven number of patients
within that stratum. After randomisation, patients and
their responsible geriatric psychiatrist or psychologist
will be informed of their allocation. The therapists
delivering the intervention will be informed which patients
can be invited for group SFT+ PMT.
Group Schema-focused therapy enriched with PMT
Two individual pre-treatment sessions without PMT
take place before the group sessions. These are meant to
make a personal treatment plan based on administering
the Young Schema Questionnaire (YSQ) and Schema
Mode Inventory (SMI) (see Mediators section below)
Fig. 1 depicts the flowchart of the study
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and to explain the concept of group SFT enriched with
PMT in more detail. The subsequent group interven-
tions comprise 20 sessions over a period of 26 weeks.
The first 18 sessions will be provided weekly after which
two follow-up sessions are given at week 22 and 26.
Each treatment session consists of a 2 h group session
SFT and 1 h group session PMT, with a 15-min break in
between. Treatment is provided according to a detailed
protocol. This protocol is highly structured and based
on the Dutch protocols short cognitive schema-focused
group therapy [36] and experiential techniques [37, 38].
During the initial group sessions, patients will be further
educated about the schema model, specifically in rela-
tion to their own three predominant schemas and cop-
ing styles (called ‘modes’ in schema focused therapy). In
the second treatment phase the patients maladaptive
schemas will be triggered and patients will be taught to
respond in a more adaptive manner. In this treatment
phase the ‘experiential imagery rescripting’ and ‘chair
interventions’ will be conducted [37, 38]. All patients re-
ceive a personal schema-focussed therapy workbook for
older adults. This workbook will be extended every ses-
sion with a summary of the session information and
homework assignments. The patients will write a weekly
summary of their therapy process and fill in a ‘severity
score form’. On this form patients rate the severity of
their 3 predominant schemas and maladaptive modes.
Based on clinical experience with older persons, geriatric
themes like loss of a role in society, loss of loved-ones,
comorbid somatic diseases and sociocultural beliefs in
the treatment of elderly, are integrated in the treatment
protocol [39, 40]. Furthermore, the protocol has been
enriched with PMT to overcome the limitations of ver-
bal therapy. During PMT, the psychomotor therapist sets
up individual and group-based physical interventions to
facilitate that patients experience their schemas and
modes. Continuity between the verbal and psychomotor
sessions is guaranteed by participation of the psycholo-
gist in the PMT as co-therapist. This way the obser-
vations pending PMT can be further analyzed in the
verbal sessions.
Treatment as usual
Treatment as usual (TAU) will be unrestricted as long as
no group SFT is provided. Usually this means that a
multidisciplinary team will determine the best treatment
for each patient. This can be either psychotherapeutic or
drug treatment, individual or group treatment, out-
patient-, day- or inpatient treatment or any combination
deemed necessary. The treatment provided will be re-
gistered, to facilitate interpretation of results. From our
clinical experience, we expect that TAU will mainly
consist of structured and supportive case-management
of personality problems or treatment restricted to
(comorbid) axis I psychiatric disorders, ideally according
to disorder specific guidelines.
Therapists, training and supervision
All interventions in the experimental group are provided
by psychologists with a minimum of 2 years post
graduate clinical training in combination with fully li-
censed and registered psychomotor therapists. During
the verbal SFT sessions, a co-therapist will participate.
Co-therapists are generally also psychologists but psy-
chotherapeutic oriented nurse practitioners experienced
in group treatment are also allowed. One of the psychologists
providing verbal SFT will also participate as co-therapist in
the PMT sessions. All psychologists and psychomotor
therapists receive a two-day training led by the first author, a
clinical psychologist who is also a licensed schema-focused
therapist. The psychomotor therapists are trained by the third
author. This training covers how to deliver a structured SFT
program, training of the SFT adaptations to older adults and
PMT techniques. The training is supported by video material
of verbal SFT and PMT techniques. All therapists receive a
manual with the treatment protocol, including a detailed
description of all sessions divided in a SFT and a
PMT section. Moreover, to improve protocol compli-
ance, the SFT-interventions provided must be ticked
off on standardized forms (part of the manual) per
session. Session attendance of the individual patients
will also be recorded by the therapists. During the
study, all therapists will participate in a monthly
supervision program provided by the first and third
author. Furthermore, all SFT and PMT group sessions
in the intervention arm will be audiotaped and saved
for evaluation. Of each therapy group two audiotapes
will be randomly selected and rated by independent
psychologists on protocol compliance. All interven-
tions listed in the treatment manual for the selected
session will be evaluated on whether or not the interven-
tion was delivered and the quality of that deliverance,
as rated on a scale ranging from 0 (not delivered) to
10 (delivered excellently). A total of at least 10 tapes
will be rated by two raters to assess the interrater reliabil-
ity, as expressed the intra class correlation coefficient
(ICC) [41].
Assessments
Data are collected at the following moments: at the
screening, baseline (T1), at the end-of-treatment (T2, i.e.
6 months after baseline for the TAU group), and finally
at 6- and 12-month follow-up (T3 and T4). Many out-
comes consist of self-report measures. Some are assessed
by structured telephone interviews conducted by re-
search assistants who will be blind about the treatment
allocation of the interviewed patient. These interviews
include assessment of socio-demographic characteristics
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and psychiatric history (at baseline only) as well as
medical consumption and costs in the past 3 months.
Personal information about potential and enrolled par-
ticipants will be stored confidentially. Table 1 shows the
questionnaires used at each assessment.
Primary outcome parameter
Psychological distress in the past week, as indicated by
the sum score of the Brief Symptom Inventory 53 item
version (BSI-53), is the primary clinical outcome param-
eter. The BSI-53 is a self-report questionnaire and an ab-
breviated version of the Symptom Checklist-90 (SCL-90)
[33, 42]. The BSI is validated for older adults and pre-
ferred over the SCL-90 since validation studies in older
adults did not indicate any information loss compared to
the SCL-90 [43]. We have chosen for psychological
distress as the primary outcome parameter since 1) older
patients with personality problems are rarely referred to
geriatric mental healthcare for personality problems spe-
cifically, but nearly always for associated affective symp-
toms and 2) the study includes patients with a variety of
personality disorders. Since the reliability of the Dutch
BSI-53 subscales is rated as good and their convergent
and divergent validity has been found to be satisfactory
[42], subscale scores will be examined as secondary out-
come parameters.
Economic evaluation
The EuroQol-5D-5 L (EQ-5D-5 L), a generic self-report
instrument, will be administered to measure health-re-
lated quality of life at the time of assessment [44]. It
consists of five questions, each related to a specific di-
mension of health status: mobility, self-care, usual activ-
ity, pain/discomfort and anxiety/depression. The utility
score of the EQ-5D-5 L will be used to calculate
Quality-Adjusted Life-Years (QALYs) [45]. Medical con-
sumption and other cost data will be collected by means
of structured telephone interviews, as previously done in
a younger patient group [44]. Since a considerable
amount of resource use is situated outside (mental)
healthcare institutions, data of formal registries such as
hospital information systems or insurer’s databases are
incomplete [44]. Therefore, patient-reported prospective
cost diaries [46] or retrospective cost interviews [47], are
Table 1 .shows the questionnaires used at each assessment
Time of assessment
Screening Baseline Post treatment assessment 6-month Follow-up 12-month
Follow- up
Primary outcomes
Psychological distress: BSI-53 X X X X
Health-related quality of life: EQ-5D-5 L X X X X
Medical consumption & costs X X X X
Secondary outcomes
Life satisfaction: Cantril’s Ladder X X X X
Mental wellbeing: WEMWBS X X X X
Personality functioning: SIPP-SF X X X X
Interoceptive body awareness: MAIA X X X X
Psychotropic drug use & treatment received
Mood variability: Mood-Zoom X X X X
Characteristics
Personality disorders: SCID-5-PD Cluster B & C X
Mental disorders: MINI-Plus X
Cognitive screening: MoCA X
Psychiatric treatment history: telephone interview X
Socio-demographics: telephone interview X
Chronic illnesses: LASA questionnaire X
Early life-events: NEMESIS questionnaire X
Alcohol use: AUDIT X
Current smoking: NEMESIS questions X
Physical activity: NEMESIS question X
Personality traits: PID-5-SF X
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the preferred instruments covering all relevant events.
We have chosen a 3-month recall interview [48, 49]
since a prospective cost diary or a recall interview over a
longer period are expected to lead to more missing
items.
Secondary outcome parameters
A number of secondary outcome parameters have been
chosen to specify the extent and nature of the effect of
group schema focused therapy in later life.
Psychotropic drug use
Data on current psychotropic drug use and changes in
between assessments will be collected as part of the tele-
phone interviews, described above.
Life satisfaction
Life satisfaction will be assessed with Cantril’s ladder, a
single self-report question to rate one’s current life situ-
ation on a scale (from 0 to 10) [50]. Life satisfaction is a
conceptualization of subjective wellbeing which stresses
the cognitive evaluation of one’s life situation, in contrast
to for example feelings such as happiness. A score of 0
indicates ‘the worst possible life for you’ and 10 ‘the best
possible life for you’.
Mental wellbeing
Mental wellbeing is assessed with the Warwick-Edinburgh
Mental Well-being Scale (WEMWBS) [51]. Mental health
and mental illness have been shown to be related but
distinct concepts [52]. Reduction or absence of men-
tal illness does not necessarily imply good mental
health and wellbeing. The WEMWBS focusses on mental
wellbeing and consists of 14 items covering positive affect,
satisfying interpersonal relationships and positive func-
tioning. Items have to be rated on a 5-point Likert
scales assessing the frequency of the positive feeling
over the past 2 weeks. A higher sum score indicates a
better mental wellbeing.
Personality functioning
Personality functioning is assessed with the Severity In-
dices of Personality Problems – Short Form (SIPP-SF)
[53]. The SIPP-SF assesses five core domains of (mal)-
adaptive personality functioning defined in the DSM-5
alternative dimensional personality disorders model,
namely: Identity Integration, Self-Control, Relational
Functioning, Social Concordance and Responsibility.
The 60-items of the questionnaire consists of proposi-
tions referring to the last three-months, which are an-
swered on four-point Likert scales, ranging from fully
agree to fully disagree. Higher scores imply more adap-
tive functioning. The SIPP-SF has been studied in an
older sample and was suggested to be a useful clinical
tool to assess effects of therapy on levels of personality
functioning in this age group [54].
Interoceptive body awareness
Interoceptive body awareness is assessed with the Multi-
dimensional Assessment of Interoceptive Awareness
(MAIA) [55]. The MAIA is a 32-item self-report ques-
tionnaire, measuring eight dimensions covering both the
ability to notice bodily sensations and to regulate their
influence on behavior. Treatment responsiveness of the
MAIA was recently shown in a study on bodily focused
contemplative training [56] which found improvements
on five of the eight MAIA scales.
Mood variability
Trying to measure emotion dysregulation in real life sit-
uations, we will assess mood variability with the
self-report Mood Zoom, an experience sampling method
for real-time mood assessment on a smartphone [57].
Participants are prompted by the phone to rate their
current mood on a screen displaying six different moods
which have to be scored on 7-point Likert scales. We
will prompt participants three times a day, at random
time points, over a one-week period per assessment.
Patient characteristics (and potential predictors of
treatment outcome)
Patient characteristics will be assessed during the screen-
ing procedure in order to verify in- and exclusion criteria
and the formal baseline assessment, to describe the study
sample, and to test and control for baseline differences be-
tween the study groups. The screening procedure includes
the formal assessment of cluster B or C personality disor-
ders, 2) comorbid mental disorders, and 3) cognitive func-
tioning. The formal baseline assessment includes 4) a
psychiatric treatment history, 5) socio-demographics, 6)
chronic somatic diseases, 7) early life events, 8) alcohol
use, 9) current smoking, 10) physical activity and 11) per-
sonality traits.
Personality disorders
Personality disorders, according to the traditional cat-
egorical DSM-5 model, will be assessed with the Struc-
tured Clinical Interview for DSM-5 for personality
disorders [31]. To minimize patient burden, the inter-
view will be limited to the general diagnostic criteria for
a personality disorder and the cluster B or C personality
disorder criteria.
Mental disorders
Comorbid psychiatric disorders will be assessed with the
aid of a DSM-5 checklist. This checklist summarizes all
DSM-5 criteria for the following disorders: Major De-
pressive Disorder, Persistent Depressive Disorder, Manic
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and Hypomanic Episodes, Bipolar Disorders type I and II,
Generalized Anxiety Disorder, Panic Disorder, Agorapho-
bia, Social Anxiety Disorder, Posttraumatic Stress Dis-
order, Obsessive Compulsive Disorder, Somatic Symptom
Disorder, and Illness Anxiety Disorder. Based on the
screening interview with the patient and all available infor-
mation in the medical records, the psychologist checks
which criteria have been present over the past 6months
and which psychiatric disorders are currently present.
Cognitive functioning
Global cognitive functioning will be assessed with the
Montreal Cognitive Assessment (MoCA). The MoCA is
a screening instrument to be administered by trained in-
terviewers (psychologist in this study) for the detection
of neurocognitive disorders and assesses a broad range
of cognitive domains. We will exclude patients with a
sum score below 23 points. A recent meta-analyses
showed that a cutoff score of 23/30 shows overall better
diagnostic accuracy and a lower false positive for the
presence of neurocognitive disorders than the initially
recommended score of 26/30 [32].
Psychiatric treatment history
Time of first treatment in mental healthcare will be
assessed in the structured telephone interview at baseline.
Chronic somatic diseases
The presence of chronic somatic diseases is assessed by
self-report questions as validated within the Longitudinal
Aging Study Amsterdam (LASA) [58, 59]. The questions
inquire about the presence of the following chronic dis-
eases: chronic non-specific lung disease, cardiac diseases,
atherosclerotic disease of the abdominal aorta or the arter-
ies of the lower limb, diabetes mellitus, cerebrovascular
disease, osteoarthritis, rheumatoid arthritis, malignant
neoplasms, high blood pressure, stomach ulcers, bowel
disorders, liver disease, epilepsy, allergies, thyroid disease,
injuries, serious head trauma, and other chronic diseases.
The LASA study shows that the accuracy of patients’
self-reports, as compared to general practitioners’ infor-
mation regarding to the presence or absence of specific
chronic diseases, is generally satisfactory [59].
Early life events
Childhood trauma will be assessed using a structured in-
ventory previously used in the Mental Health Survey and
Incidence Study (NEMESIS) [60]. In this inventory partici-
pants are asked whether they have experienced any kind of
neglect or abuse before the age of 16. Covered are: emo-
tional neglect, which includes the lack of parental attention
or support and interest in one’s problems and experiences;
psychological abuse, which includes verbal abuse, punish-
ment without reason, subordination to siblings and being
blackmailed; physical abuse, which includes being kicked,
hit with or without an object and any other physical harm;
and sexual abuse, which is defined as being sexually
touched against one’s will, or being forced to touch some-
one sexually. After an affirmative answer, a question is
asked about the frequency of these events, to be recorded
as: never, once, sometimes, regularly, often or very often. A
childhood abuse index can be constructed by recoding the
frequency scores in (0) never, (1) once, sometimes and (2)
regularly, often or very often. The scores of each of the four
domains of abuse will be summed, resulting in a childhood
abuse index which ranges from 0 to 8. Early life-events will
be additionally measured and include divorce of parents,
placement in children’s home, juvenile prison or foster care,
and walking away from home.
Lifestyle characteristics
Alcohol use will be assessed with the Alcohol Use Dis-
order Identification Test (AUDIT) [61], a screening
questionnaire for alcohol-related problems in the past
year. Current smoking and physical activity will be
assessed by two single questions from NEMESIS on
current smoking and number of hours per week spent in
physical exercise or sport lately, not counting sedentary
pursuits such as chess or fishing [60].
Personality traits
Pathological personality traits are a second dimension of
the DSM-5 alternative dimensional model for personality
disorders and can be measured with the 220-item Per-
sonality Inventory for DSM-5 (PID-5) [62]. The PID-5
covers 25 pathological personality trait facets, which can
be combined to obtain scores for five higher-order do-
mains distinguished. These domains are related to the
traditional big five personality traits and to concepts
from schema-focused therapy [63]. Most items of the
PID-5 are age neutral and thus can be used in older
adults [64]. Recently, the PID-5-Short Form (PID-5-SF)
has been validated, yielding nearly identical reliability
and validity as the long form in scoring the DSM-5 do-
mains and facets [63]. This version will be applied in the
present study to minimize patient burden. All items are
rated on four-point Likert scales from 0 (very false or
often false) to 3 (very true or often true). The combin-
ation of pathological personality traits (PID-5-SF) and
impaired personality functioning (SIPP-SF) results in the
alternative DSM-5 model personality disorder diagnoses.
Mediators
We will examine whether any improvement on the pri-
mary and secondary outcome parameters in patients re-
ceiving the experimental schema therapy can be
attributed to (i.e. is mediated by) improvements in the
therapy specific targets. Mediators are early maladaptive
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schemes and schema modes, which will be assessed,in
the experimental group only, pre-treatment (i.e. in the
two initial, individual sessions of treatment) and 3, 6 and
12months post-baseline, and schemas and modes sever-
ity scores, which will be assessed during treatment on a
weekly basis.
Early maladaptive schemas
Early maladaptive schemas will be assessed with the
self-report Young Schema Questionnaire second version
(YSQ-2) [65–68]. The YSQ-2 is the most commonly
used measure of early maladaptive schemas [65]. The
YSQ-2 consists of 205 items, to be rated along a 6-point
Likert scale, which measures the severity of 16 maladap-
tive schemas. The Dutch YSQ-2 has good reliability and
convergent and discriminant validity [69].
Schema modes
Schema modes will be assessed with the Schema Mode
Inventory (SMI), a 118-item, self-report questionnaire
measuring 16 modes [65]. These modes can be divided
into 4 types: healthy modes, parent modes, child modes
and coping modes. All items are rated on a 6-point
Likert scale. The Dutch SMI has an excellent test-retest
reliability and the convergent and divergent validity of
the subscales are satisfactory [70].
Schema and modes severity scores
Patients will rate the severity of their three most domin-
ant schemas and modes on a scale from 0 (no burden at
all) to 10 (a lot of burden) on a weekly basis.
Analyses
Analyses will be conducted according to the
intention-to-treat principle. Differences between the
intervention and control group on the various outcome
measures (BSI-53, EQ-5D-5 L, secondary outcome pa-
rameters) will be analyzed using linear mixed-models,
more specifically random coefficient analysis, which ac-
counts for missing observations [71]. In these analyses,
study site and patient will be included as random effects
(with observations nested in patients and patients nested
in study sites) and study arm and full versus subthresh-
old personality disorder as fixed effects. Interactions will
be tested 1) between time of observation and study arm
and 2) between this interaction and full versus sub-
threshold personality disorder, to check whether the
intervention effect is different for patients with a full or
subthreshold personality disorder. All analyses will be
controlled for the baseline population characteristics
described above.
Economic evaluation and budget impact analysis
The cost-effectiveness analysis will be performed along-
side the clinical trial to assess the cost-effectiveness of
group SFT + PMT versus TAU. The cost-effectiveness
analysis will result in two separate incremental
cost-effectiveness ratios (ICERs) for group SFT + PMT
compared to TAU, i.e. incremental costs per additional
point improvement on the BSI-53, and incremental costs
per Quality Adjusted Life Year (QALY) gained. The ana-
lysis will be performed taking a societal perspective and
with a time horizon of 18 months. Costs and effects will
be discounted according to Dutch guidelines [45]. Uni-
variate sensitivity analyses will investigate the impact of in-
dividual assumptions and parameters (e.g. costs of SFT +
PMT and other elements). To quantify the uncertainty
around the ICERs, bootstrap resampling will be performed.
Results will be presented as tornado diagrams and
cost-effectiveness acceptability curves, the latter represent-
ing the probability that group SFT + PMT is cost-effective
given a certain value of ‘willingness to pay’ for a QALY (or
one point improvement on the BSI). Included costs will be
those of group SFT enriched with PMT, other forms of psy-
chotherapy, hospital admissions, medication, outpatient
visits, General practitioner visits, home care, and lost prod-
uctivity from both paid and unpaid work. Unit prices will
be determined according to Dutch guidelines [45].
A budget impact analysis will be performed to inform
decision makers on the financial consequences of the
adoption and diffusion of group STF + PMT in the
Dutch health care system. The analysis will be per-
formed according to the most recent principles of the
ISPOR task force [72] and Dutch guidelines [45]. The
trial results will be extrapolated to a time horizon of 5
years, and for the entire Dutch population concerned.
Aging of the population will be taken into account. Sen-
sitivity analysis will explore several scenarios, regarding
speed of uptake of the therapy in clinical practice and
patients’ willingness to participate.
Discussion
This paper presents the design of the first randomized
controlled trial evaluating the effectiveness of group SFT
enriched with PMT, for older adults with personality
disorders. To date, only uncontrolled studies on the
treatment of personality disorders have been conducted
in this age-group [21, 25]. This RCT is especially rele-
vant in the light of aforementioned underdetection and
undertreatment of personality disorders in later life [10].
Nonetheless, we faced many choices when designing the
protocol, since group SFT has rapidly evolved over the
past decades and its applications have even broadened
beyond personality disorders alone. Below the most im-
portant choices will be discussed.
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Group versus individual format
Evaluation of group therapy within a randomized con-
trolled design may result in some difficulties. First, suffi-
cient patients have to provide informed consent before
the therapy can start. This may lead to early dropouts
when recruitment is slow at some study sites and
waiting period becomes long. Secondly, some patients
are reluctant towards group therapy. This may be espe-
cially so for older people, who easily feel they have to
‘hang themselves out to dry’ [73]. Nonetheless, we have
taken the risk of non-participation as delivering SFT in a
group format has many advantages. First, a group
process may speed up the therapeutic process [74]. Sec-
ondly, group therapy may counterbalance loneliness, a
frequently encountered problem in later life [75] espe-
cially among personality disordered persons. Thirdly, a
group format is more efficient from an economic per-
spective [76] as well as in light of the scarcity of geron-
topsychologists [77].
Choice of control group
The choice of an adequate control group is critical when
designing a randomized controlled trial. Since personal-
ity disorders usually remain largely undetected in geriat-
ric psychiatry and treatment is generally focused on the
manifest affective symptoms, we considered comparison
to usual care as most appropriate. Even if the mere
provision of attention would explain a positive effect of
our therapy, this may imply that treatment intensity in
geriatric psychiatry in general is too low. Alternative op-
tions were disqualified for the following reasons. Firstly,
an active control group to control for attention is gener-
ally desired in psychotherapeutic research [78]. Ideally,
two effective therapies would be compared searching for
the most effective treatment modality. However, for
none of the available therapies for personality disorders,
effectiveness is proven in geriatric psychiatry. When no
differences are found then, this could easily lead to the
wrong conclusion that both therapies are probably non-
effective, and to withholding of effective treatment
from older patients with personality disorders. Sec-
ondly, a waiting-list control group was dismissed for
two reasons. First, the placebo-effect or spontaneous
recovery may even be reduced by a waiting list [79].
Second, personality pathology is associated with a
high disease burden and when referred to specialized
mental health care, a waiting list of 18 months was
not deemed acceptable. Finally, from an economic
perspective, it is always more informative to assess
cost-effectiveness of an intervention as compared to care
as usual, since this best approaches the real-world
situation if the intervention were to be implemented in
routine clinical practice.
Enrichment with PMT.
Arguments for the addition of PMT have already been
given in both the introduction and methods of this art-
icle. Nonetheless, this step is probably most debatable as
even among younger patients no examples of this com-
bination have been reported. However, pure cognitive in-
terventions are generally less effective in later life [80]
and older persons generally have more difficulties in ex-
pressing their emotions and feelings verbally than youn-
ger persons [81]. In our protocol we added PMT and
experiential techniques and provided it to 5 pilot groups
who reported a potential surplus value for the experien-
tial techniques and PMT. The continuity of one of the
group therapists who also attends the PMT sessions was
highly appreciated.
Primary outcome parameter
Although group SFT focuses on personality change, we
did not choose personality (dys)functioning as primary
outcome parameter for several reasons. First, we did not
restrict our study population to one personality disorder
specifically. Many studies on SFT are restricted to bor-
derline personality disorder. In those studies, it is ra-
tional to consider the severity of borderline personality
pathology as the primary outcome parameter. In studies
with mixed personality disorders, however, this becomes
less suitable. Moreover, most personality pathology in-
struments are multidimensional and therefore difficult
to consider as primary outcome parameter. And taking
recovery, defined as not meeting the DSM-criteria for a
personality disorder anymore, as the overarching out-
come measure, would mean that a semi-structured diag-
nostic interview should be repeated at each follow-up
assessment, which is time-consuming and could increase
patient dropout. Second, in geriatric psychiatry most pa-
tients with a personality disorder are referred to special-
ized mental health care for disabling affective symptoms
[30]. Specific treatment for personality disorders is often
not available and rarely offered in old age psychiatric
services. So the majority of older patients with personal-
ity disorders receive pharmacotherapy with or without
nurse-led supportive care for an affective disorder,
although psychotherapy is the preferred treatment for
the underlying personality disorder according to clinical
guidelines [45]. This is a situation which calls for a
change, as meta-analyses among younger age groups
have shown that comorbid personality disorders worsen
the prognosis of affective disorders and predict relapse
[82]. Moreover, previous studies on SFT in both younger
and older patients have reported large effect-sizes for
improvement of general distress [83]. Earlier research
focused mainly on the cognitive variant of (group) SFT
for treatment of personality disorders in younger and
middle-aged adults (< 60 years). This cognitive variant
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may be somewhat less effective for older adults (> 60
years). This study will provide an answer to the question
whether group SFT enriched with PMT adapted to the
needs of for older adults with cluster b and/or c person-
ality is effective and cost-effective. Acknowledging the
numerous methodological choices that have to be made,
we hope to motivate other researchers to conduct also
RCT’s on the (cost-)effectiveness of the different psycho-
therapies in older adults with personality disorders.
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